Skip to content

Can people with resistant HIV omit NRTIs when switching from a failing regimen?

Karen Tashima, Brown University, presenting at CROI 2013. © Liz Highleyman / hivandhepatitis.com

Australian researchers project that many HIV-positive people will run out of treatment options

Prevalence of drug-resistant HIV has fallen dramatically among antiretroviral-experienced patients in Western Europe

Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure

The generic generation

Glucose metabolism worsens in HIV treatment-experienced taking NRTI-sparing regimens

Once-daily elvitegravir works as well as raltegravir at 96 weeks

Once-daily elvitegravir matches raltegravir

Little evidence of transmission of virus that's resistant to newer anti-HIV drugs